BCTX

Briacell Therapeutics
BCTX

$1.36
3.82%
 

About: BriaCell Therapeutics Corp is an immuno-oncology-focused biotechnology company. The group develops targeted and safe approaches for the management of cancer. BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT in metastatic breast cancer. Additionally, it is developing Bria-OTS, off-the-shelf personalized immunotherapy, for the treatment of advance-stage breast cancer by matching the patient's HLA type.

Employees: 12

0
Funds holding %
of 6,689 funds
0
Analysts bullish %
of 3 analysts
0
News positive %
of 4 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

1,014% more call options, than puts

Call options by funds: $672K | Put options by funds: $60.3K

33% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 6

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 1 (+0) [Q1 2024]

1.69% less ownership

Funds ownership: 15.42% [Q4 2023] → 13.73% (-1.69%) [Q1 2024]

20% less funds holding

Funds holding: 25 [Q4 2023] → 20 (-5) [Q1 2024]

56% less capital invested

Capital invested by funds: $14.4M [Q4 2023] → $6.38M (-$8.04M) [Q1 2024]

83% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 6

Research analyst outlook

3 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$18
1,224%
upside
Avg. target
$18
1,224%
upside
High target
$18
1,224%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Emily Bodnar
1,224%upside
$18
Buy
Reiterated
4 Jun 2024
HC Wainwright & Co.
Emily Bodnar
1,224%upside
$18
Buy
Reiterated
24 May 2024
HC Wainwright & Co.
Emily Bodnar
1,224%upside
$18
Buy
Reiterated
28 Dec 2023

Financial journalist opinion

Based on 4 articles about BCTX published over the past 30 days